Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c

Ivan Bank; Marlène H. W. van de Poel; Michiel Coppens; Karly Hamulyák; Martin H. Prins; Jan van der Meer; Nic J. G. M. Veeger; Harry R. Büller; Saskia Middeldorp

doi:10.1160/TH07-04-0293

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 98(05): 1040-1044
DOI: 10.1160/TH07-04-0293

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c

A prospective family cohort study

Ivan Bank

¹Department of Vascular Medicine, Academic Medical Center, University of Amsterdam

,

Marlène H. W. van de Poel

²Department of Hematology, Division of Hemostasis, Thrombosis, and Rheology, University Hospital Groningen

,

Michiel Coppens

¹Department of Vascular Medicine, Academic Medical Center, University of Amsterdam

,

Karly Hamulyák

³Department of Hematology, University Hospital of Maastricht, Maastricht

,

Martin H. Prins

⁴Department of Clinical Epidemiology and Medical Technology Assessment, University Hospital of Maastricht, Maastricht; The Netherlands

,

Jan van der Meer

³Department of Hematology, University Hospital of Maastricht, Maastricht

,

Nic J. G. M. Veeger

³Department of Hematology, University Hospital of Maastricht, Maastricht

,

Harry R. Büller

¹Department of Vascular Medicine, Academic Medical Center, University of Amsterdam

,

Saskia Middeldorp

¹Department of Vascular Medicine, Academic Medical Center, University of Amsterdam

› Author Affiliations

Abstract

Summary

Elevated levels of factor VIII:c (elevated FVIII:c) are associated with an increased risk for venous thromboembolism (VTE) and arterial vascular events, and are at least in part determined genetically. We prospectively followed 192 asymptomatic individuals with elevated FVIII:c (>150%) and 340 with normal levels for an average duration of 31 months (range 7 to 56 months) to investigate the risk of VTE and arterial vascular events. Participants were first degree relatives of consecutive patients with elevated FVIII:c and VTE or arterial vascular events before the age of 50 years. The incidences ofVTE were 1.25% (0.46–2.73) per year in the subjects with elevated FVIII:c, versus 0.23% (0.03–0.82) in those with normal levels (OR 5.5 [1.1–27.3]). The annual incidences of arterial vascular events were 1.04% (0.34–2.42) and 0.23% (0.03–0.82) in relatives with and without elevated levels of FVIII:c, respectively (OR: 4.5 [0.9–23.5]). After adjustment for age, smoking, known diabetes mellitus, hyperlipidemia, and hypertension, the odds ratio for any event was 3.7 (1.1–13.1). In conclusion, asymptomatic individuals with elevated FVIII:c levels and a positive family history of VTE or arterial vascular events before the age of 50 appear to have a high annual incidence of first VTE and arterial vascular events. Elevated FVIII:c may be a common risk factor for both clinical entities.

Keywords

Elevated FVIII:c - venous thromboembolism - arterial vascular events - family cohort study

Full Text

References

References
1 Cortellaro M, Boschetti C, Cofrancesco E. et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb 1992; 12: 1063-1070.
2 Koster T, Blann AD, Briet E. et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
3 O’Donnell J, Tuddenham EG, Manning R. et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 825-828.
4 Folsom AR, Rosamond WD, Shahar E. et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999; 100: 736-742.
5 Tracy RP, Arnold AM, Ettinger W. et al. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 1999; 19: 1776-1783.
6 Kraaijenhagen RA, in ’t Anker PS, Koopman MM. et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
7 Kyrle PA, Minar E, Hirschl M. et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-462.
8 Kamphuisen PW, Houwing-Duistermaat J, van Houwelingen HC. et al. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 1998; 79: 323-327.
9 Kamphuisen PW, Lensen R, Houwing-Duistermaat J. et al. Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. Br J Haematol 2000; 109: 19-22.
10 Berger M, Mattheisen M, Kulle B. et al. High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. Blood 2005; 105: 638-644.
11 Bank I, Libourel EJ, Middeldorp S. et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.
12 Prandoni P, Ghirarduzzi A, Prins MH. et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Hamost 2006; 4: 1891-1896.
13 Goon PKY, Lip GYH. Arterial disease and venous thromboembolism: a modern paradigm?. Thromb Haemost 2006; 96: 111-112.
14 Pan WH, Bai CH, Chen JR. et al. Associations between carotid atherosclerosis and high factor VIII activity, dyslipidemia, and hypertension. Stroke 1997; 28: 88-94.
15 Sanson BJ, Simioni P, Tormene D. et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999; 94: 3702-3706.
16 Middeldorp S, Meinardi JR, Koopman MM. et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135: 322-327.
17 Coppens M, van de Poel MH, Bank I. et al. A prospective cohort study on the absolute incidence Of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 2006; 108: 2604-2607.
18 Vossen CY, Rosendaal FR. Risk of arterial thrombosis in carriers of familial thrombophilia. J Thromb Hamost 2006; 4: 916-918.
19 Kamphuisen PW, Eikenboom JC, Vos HL. et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-683.
20 Kreuz W, Stoll MJR, Heinecke A. et al. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome:results of a multicenter study. Arterioscler Thromb Vasc Biol 2006; 26: 1901-1906.